Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Safety, tolerability and pharmacokinetics following repeated doses (15-day dosing)

Phase 1

Boehringer Ingelheim